Caris Life Sciences, Inc. Common Stock
Here’s whether Caris Life Sciences, Inc. Common Stock (CAI) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 46 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-1.75% over 10 days); 3-month momentum negative (-20.8%). Currently 56.5% off its 52-week high. Score: -4/7.
CAI is trading below its 200-day MA ($26.53) — a key warning sign the longer-term trend is under pressure. An RSI of 46.4 sits in the neutral zone — momentum is neither stretched nor exhausted. With ~10 months of trading history, the return since first available bar is -34.0%. The current 56.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.